•RELACOEM is the first study conducted in LATAM evaluating risk of COVID-19 in patients with MS and NMOSD•We found an increased proportion of hospitalizations in NMOSD when compared to MS patients.•MS patient mortality in our series was lower compared to another MS patient's cohort•One third of NMOSD patients died, all on Rituximab treatment.